Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-373.63M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -219.39% |
| Return on Assets (Trailing 12 Months) | -98.75% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.28 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $20.53 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-5.68 |
| Earnings per Share (Most Recent Fiscal Year) | $-19.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $-19.94 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 19.90M |
| Free Float | 15.14M |
| Market Capitalization | $4.07B |
| Average Volume (Last 20 Days) | 0.37M |
| Beta (Past 60 Months) | -0.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.92% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |